ProMetic Life Sciences Confirms FDA Approval for Octaplas®

ProMetic Life Sciences Inc. (TSX: PLI) announced that it has obtained confirmation from Octapharma about the regulatory approval of plasma product Octaplas®.

As quoted in the press release:

ProMetic’s proprietary prion capture resin, PrioClearTM, is incorporated in Octapharma’s manufacturing process for its solvent/detergent treated, prion-reduced, plasma product, Octaplas®.

ProMetic received purchase orders from Octapharma exceeding $6 million for PrioClearTM resin in 2012 for approved European countries and to support product launch in new European territories.

Click here to read the full ProMetic Life Sciences Inc. (TSX: PLI) press release.